Gila Therapeutics is a clinical stage pharmaceutical company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes, and associated metabolic disorders.

Gila’s topical lingual delivery activates satiety centers in the brain with no systemic exposure – by leveraging previously unknown connections between the tongue and the brain – thus, avoiding the risks and safety concerns endemic to all systemically delivered therapeutics.

Gila’s first program, GT 01: Topical Lingual PYY is entering Phase II proof of concept clinical trials on the heels of a highly successful Phase I which showed strong efficacy with literally zero treatment-related AEs or SAEs. Multiple topical lingual hormone targets are currently under development, including: GLP-1, amylin, leptin and others.

The company is headquartered in Boston, MA.